로딩 중…
지수 로딩 중…
ILYANG PHARMACEUTICAL CO.,LTD
007570· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩6,950-0.14%
2026-11-02
Financials
Valuation Metrics
ILYANG PHARMACEUTICAL CO.,LTD's Market Cap is ₩1363B. At end of 2025 it was ₩2844B. Ranked #1024 of 2,405 in KR market (top 43%), #506 of 778 on KOSPI (top 65%), #121 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 52%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 136.26B KRW | KR#1,024/2,405 Sec#121/231 |
| Revenue | 277.96B KRW | KR#862/2,405 Sec#41/231 |
| Net Income | 17.36B KRW | KR#758/2,405 Sec#51/231 |
| Total Assets | 451.72B KRW | KR#822/2,405 Sec#49/231 |
| Net Assets | 256.94B KRW | KR#811/2,405 Sec#52/231 |
| Employees | 668 | KR#374/2,405 Sec#32/231 |
| Value | ||
| P/E | 7.85x | KR#696/2,405 Sec#30/231 |
| P/B | 0.53x | KR#928/2,405 Sec#52/231 |
| PEG | 0.12x | KR#462/2,405 Sec#24/231 |
| P/S | 0.49x | KR#959/2,405 Sec#46/231 |
| FCF Yield | 4.64% | KR#900/2,405 Sec#53/231 |
| Profitability | ||
| ROE | 6.76% | KR#906/2,405 Sec#62/231 |
| ROA | 3.84% | KR#907/2,405 Sec#75/231 |
| Op. Margin | -4.94% | KR#1,844/2,405 Sec#123/231 |
| Revenue Growth | 19.63% | KR#559/2,405 Sec#53/231 |
| Earnings Growth | 67.20% | KR#492/2,405 Sec#32/231 |
| Financial Health | ||
| Debt Ratio | 75.81% | KR#1,284/2,405 Sec#155/231 |
| Total Debt | 177.93B KRW | KR#545/2,405 Sec#29/231 |
| FCF | 6.32B KRW | KR#839/2,405 Sec#55/231 |
| Cash | 12.87B KRW | KR#1,545/2,405 Sec#126/231 |
| Current Ratio | 0.88x | KR#1,852/2,405 Sec#182/231 |
| Dividend | ||
| Div. Yield | 2.23% | KR#870/2,405 Sec#44/231 |
| Div. Growth | 3.33% | KR#668/2,405 Sec#36/231 |
| Performance | ||
| 1Y Return | -52.40% | KR#2,024/2,405 Sec#175/231 |
| 1M Return | -13.99% | KR#1,493/2,405 Sec#152/231 |
| From 52W High | -57.20% | KR#1,517/2,405 Sec#123/231 |
| 1Y MDD | -52.67% | KR#1,074/2,405 Sec#89/231 |
| Trading | ||
| Volume | 10,508 shares | KR#1,819/2,405 Sec#179/231 |
| Trading Value | 73.3M KRW | KR#1,549/2,405 Sec#161/231 |
| Foreign Own. | 5.49% | KR#796/2,405 Sec#74/231 |
| Per Share | ||
| EPS | 885 KRW | KR#775/2,405 Sec#53/231 |
| BPS | 13,105 KRW | KR#795/2,405 Sec#53/231 |
Company Info
동사는 1946년 설립, 1971년 법인 전환 후 2009년 일양바이오팜(주) 설립과 함께 중국 시장 진출을 위해 일양약품(길림)유한공사를 신설하였음. 제14호 신약 놀텍, 제18호 신약 슈펙트, 계절독감백신 등의 전문의약품과 원비디 등 일반의약품, 원료의약품, 건강보조식품을 제조판매하고 있음. 시장점유율 증대를 위한 R&D 투자와 글로벌 혁신의약품 개발을 최우선으로 하고 있음. 일양약품는 1946년에 설립되었으며 경기도 용인시에 본사를 두고 있습니다.